Radiation therapy for advanced prostate cancer not responding to hormone therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding radiation therapy to the prostate and cancer spread sites helps men whose prostate cancer has spread to bones but isn't responding well to standard hormone treatments. You'd be eligible if your PSA level (a cancer marker) stays high after six months of dual hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Prostate cancer that spread to at least 4 bones when first diagnosed
- Completed 6 months of combination hormone therapy (two types of drugs)
- PSA level above 0.2 ng/ml after 6 months of hormone therapy
- Cancer spread only to bones and lymph nodes, not to organs like lungs or liver
- Fewer than 16 spots of cancer on recent imaging scans
- No prior radiation therapy to the pelvis area
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.